Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Leases (2019 - 2025)

BioNexus Gene Lab's Leases history spans 7 years, with the latest figure at $186082.0 for Q3 2025.

  • For Q3 2025, Leases fell 20.05% year-over-year to $186082.0; the TTM value through Sep 2025 reached $186082.0, down 20.05%, while the annual FY2024 figure was $215243.0, 52.07% up from the prior year.
  • Leases for Q3 2025 was $186082.0 at BioNexus Gene Lab, down from $200284.0 in the prior quarter.
  • Across five years, Leases topped out at $241700.0 in Q2 2024 and bottomed at $24975.0 in Q3 2022.
  • The 5-year median for Leases is $55747.0 (2021), against an average of $111992.8.
  • The largest annual shift saw Leases crashed 44.02% in 2022 before it surged 466.74% in 2023.
  • A 5-year view of Leases shows it stood at $41090.0 in 2021, then surged by 35.63% to $55730.0 in 2022, then soared by 153.98% to $141544.0 in 2023, then skyrocketed by 52.07% to $215243.0 in 2024, then dropped by 13.55% to $186082.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Leases are $186082.0 (Q3 2025), $200284.0 (Q2 2025), and $203923.0 (Q1 2025).